KMTS (Kestra Medical Technologies) Additional Paid-In Capital: $853.35 Mil(As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KMTS Kestra Medical Technologies Ltd KMTS
12 GF Score
Price $25.63
! 6 Warning Signs
View Full Analysis

What is Kestra Medical Technologies Additional Paid-In Capital?

Kestra Medical Technologies KMTS -0.70% 12 Additional Paid-In Capital is $853.35 Mil as of Apr. 2026. GuruFocus rates KMTS with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.


Kestra Medical Technologies's quarterly additional paid-in capital increased from Oct. 2025 ($691.49 Mil) to Jan. 2026 ($842.67 Mil) and increased from Jan. 2026 ($842.67 Mil) to Apr. 2026 ($853.35 Mil).

Kestra Medical Technologies's annual additional paid-in capital increased from Apr. 2024 ($177.15 Mil) to Apr. 2025 ($674.31 Mil) and increased from Apr. 2025 ($674.31 Mil) to Apr. 2026 ($853.35 Mil).

Kestra Medical Technologies Additional Paid-In Capital Related Terms

Kestra Medical Technologies Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Kestra Medical Technologies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kestra Medical Technologies Additional Paid-In Capital Chart

Kestra Medical Technologies Annual Data
Trend Apr20 Apr21 Apr23 Apr24 Apr25 Apr26
Additional Paid-In Capital
Get a 7-Day Free Trial 171.85 194.74 177.15 674.31 853.35

Kestra Medical Technologies Quarterly Data
Apr20 Jul20 Apr21 Jul21 Apr23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 674.31 678.89 691.49 842.67 853.35
KMTS
12GF Score
Kestra Medical Technologies Ltd KMTS
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kestra Medical Technologies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $853.35 Mil mean?
Kestra Medical Technologies (KMTS) has a Additional Paid-In Capital of $853.35 Mil as of Apr. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Kestra Medical Technologies and its competitors.
Is Kestra Medical Technologies' Additional Paid-In Capital too high?
Kestra Medical Technologies' current Additional Paid-In Capital is $853.35 Mil. Overall, Kestra Medical Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Additional Paid-In Capital compare to AZTA and STAA?
Kestra Medical Technologies' Additional Paid-In Capital of $853.35 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Medical Devices & Instruments company?
A good Additional Paid-In Capital depends on the Medical Devices & Instruments industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Kestra Medical Technologies and its competitors. Kestra Medical Technologies's current Additional Paid-In Capital is $853.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Additional Paid-In Capital of $853.35 Mil. The current Additional Paid-In Capital is $853.35 Mil. Kestra Medical Technologies' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Additional Paid-In Capital is $853.35 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kestra Medical Technologies Business Description

Address 3933 Lake Washington Boulevard NE, Suite 200, Kirkland, WA, USA, 98033
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
12GF Score

Get the complete analysis for KMTS

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.63
Price